文献速递儿科与产科急症消化、代谢与肾脏急症

儿童胃肠炎急诊就诊后多剂昂丹司琼的应用

Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis.
PubMed 文献 · N Engl J Med · 2025-01-01
一句话结论儿童胃肠炎呕吐急诊就诊后带回家口服昂丹司琼6剂,可降低随后7天中重度胃肠炎风险(5.1% vs 12.5%)。

这项双盲随机优效性试验在6个儿科急诊科纳入1030例6月龄至18岁以下急性胃肠炎伴呕吐患儿,出院时提供6剂口服昂丹司琼或安慰剂,用于入组后48小时内呕吐时服用。主要终点为入组后7天内改良Vesikari量表评分≥9分的中重度胃肠炎,昂丹司琼组5.1%(23/452)vs 安慰剂组12.5%(55/441),未校正风险差-7.4个百分点(95%CI -11.2至-3.7),校正后OR 0.50(95%CI 0.40至0.60)。入组后48小时内呕吐总次数昂丹司琼组更低(校正率比0.76,95%CI 0.67至0.87),但呕吐存在与否及中位呕吐持续时间两组无有意义差异;非计划就诊率、静脉输液率及不良事件发生率两组无实质性差异(OR 0.99,95%CI 0.61至1.61)。

要点

  • 儿童胃肠炎呕吐急诊就诊后带回家口服昂丹司琼6剂,7天内中重度胃肠炎(改良Vesikari评分≥9分)发生率5.1%(23/452)vs 安慰剂12.5%(55/441),未校正风险差-7.4个百分点(95%CI -11.2至-3.7)。
  • 校正院区、体重和缺失数据后,昂丹司琼组中重度胃肠炎风险低于安慰剂组(校正OR 0.50,95%CI 0.40至0.60)。
  • 入组后48小时内呕吐总次数昂丹司琼组低于安慰剂组(校正率比0.76,95%CI 0.67至0.87),但呕吐存在与否及中位呕吐持续时间两组无有意义差异。
  • 入组后非计划就诊率与静脉输液率两组无实质性差异,不良事件发生率两组无有意义差异(OR 0.99,95%CI 0.61至1.61)。
  • 研究对象为6月龄至18岁以下急性胃肠炎伴呕吐患儿,来自6个儿科急诊科,出院时提供6剂口服昂丹司琼或安慰剂,用于入组后48小时内持续呕吐时服用。

适用人群与场景

  • 6月龄至18岁以下急性胃肠炎伴呕吐患儿,就诊于6个儿科急诊科。
  • 出院时由照护者获得6剂口服昂丹司琼或安慰剂,用于入组后48小时内持续呕吐时服用。

诊断标准与关键阈值

  • 主要终点中重度胃肠炎定义为入组后7天内改良Vesikari量表评分≥9分(量表范围0至20分,分值越高病情越重)。

处置流程与药物剂量

  • 出院时向照护者提供6剂口服昂丹司琼或安慰剂,在入组后48小时内针对持续呕吐服用。

研究设计与关键结果

  • 双盲随机优效性试验,1030例患儿随机,来自6个儿科急诊科,人群为6月龄至18岁以下急性胃肠炎伴呕吐患儿。
  • 主要终点中重度胃肠炎(改良Vesikari评分≥9分)发生率:昂丹司琼组5.1%(23/452)vs 安慰剂组12.5%(55/441),未校正风险差-7.4个百分点(95%CI -11.2至-3.7)。
  • 校正院区、体重和缺失数据后,昂丹司琼组中重度胃肠炎风险低于安慰剂组(校正OR 0.50,95%CI 0.40至0.60)。
  • 入组后48小时内呕吐总次数昂丹司琼组低于安慰剂组(校正率比0.76,95%CI 0.67至0.87);呕吐存在与否及中位呕吐持续时间两组无有意义差异。
  • 入组后7天内非计划就诊率及静脉输液率两组无实质性差异;不良事件发生率两组无有意义差异(OR 0.99,95%CI 0.61至1.61)。

证据类型、等级与局限

  • 证据类型:双盲随机优效性试验(ClinicalTrials.gov NCT03851835),由加拿大健康研究院等资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急诊就诊的急性胃肠炎伴呕吐患儿,出院时提供多剂口服昂丹司琼可降低随后7天中重度胃肠炎风险(5.1% vs 12.5%),作者结论支持这一做法。
  • 昂丹司琼未能减少呕吐的存在或缩短中位呕吐持续时间,但减少了48小时内呕吐总次数(校正率比0.76)。
  • 非计划就诊率、静脉输液率及不良事件发生率两组无实质性差异,提示出院后多剂昂丹司琼未增加上述风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ondansetron improves outcomes when administered in emergency departments to children with acute gastroenteritis-associated vomiting. It is commonly prescribed at discharge to reduce symptoms, but evidence to support this practice is limited.

METHODS: We conducted a double-blind, randomized superiority trial involving children 6 months to less than 18 years of age with acute gastroenteritis-associated vomiting in six pediatric emergency departments. Caregivers were provided with six doses of oral ondansetron or placebo to administer in response to ongoing vomiting during the first 48 hours after enrollment. The primary outcome was moderate-to-severe gastroenteritis, defined by a score of 9 or higher on the modified Vesikari scale (scores range from 0 to 20, with higher scores indicating greater severity), during the 7 days after enrollment. Secondary outcomes included the presence of vomiting, the duration of vomiting (defined as the time from enrollment to the last vomiting episode), the number of vomiting episodes within 48 hours after enrollment, unscheduled physician visits within 7 days after enrollment, and receipt of intravenous fluids.

RESULTS: A total of 1030 children underwent randomization. Moderate-to-severe gastroenteritis occurred in 5.1% (23 of 452 participants for whom data were available) in the ondansetron group and 12.5% (55 of 441) in the placebo group (unadjusted risk difference, -7.4 percentage points; 95% confidence interval [CI], -11.2 to -3.7). After adjustment for site, weight, and missing data, ondansetron was associated with a lower risk of moderate-to-severe gastroenteritis than placebo (adjusted odds ratio, 0.50; 95% CI, 0.40 to 0.60). Although we did not observe any meaningful difference between the groups in the presence or median duration of vomiting, the total number of vomiting episodes within 48 hours after enrollment was lower with ondansetron than with placebo (adjusted rate ratio, 0.76; 95% CI, 0.67 to 0.87). The percentage of children who had unscheduled health care visits and the percentage who received intravenous fluids after enrollment did not differ substantially between the groups. The incidence of adverse events also did not differ meaningfully between the groups (odds ratio, 0.99; 95% CI, 0.61 to 1.61).

CONCLUSIONS: Among children with gastroenteritis-associated vomiting, the provision of ondansetron after an emergency department visit led to lower risk of moderate-to-severe gastroenteritis during the subsequent 7 days than the provision of placebo. (Funded by the Canadian Institutes of Health Research and others; ClinicalTrials.gov number, NCT03851835.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Freedman SB, Williamson-Urquhart S, Plint AC, et al. Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis. N Engl J Med. 2025. PMID: 40673584. doi:10.1056/NEJMoa2503596

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。